Opinion|Videos|April 22, 2024
Dyskinesia: Importance of Giving Patients More Good “On- Time" In Parkinson’s Disease
Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.
Advertisement
Timecodes:
1:28 Defining ON time in PD
4:50 Dyskinesia experience
8:00 Tremor and dyskinesia
13:30 Dyskinesia and QoL
16:00 Dyskinesia and OFF
19:30 Tailoring treatment
22:00 Amantadine DR/ER
29:00 Amantadine candidates
Advertisement
Related to this article
Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class
3
Myelin Repair Research in MS: Lessons From Clinical Trials and the Road Ahead
4
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
5